Global Haemophilia Therapeutics Market

Increased use of recombinant and prophylaxis therapies drives growth

USD 3,950

* Required Fields

USD 3,950

PAY BY INVOICE

Be the first to review this product

This research service focuses on the global haemophilia therapeutics market, with a particular focus on recently FDA-approved drugs and late-stage compounds for the treatment of haemophilia A, haemophilia B, inhibitors, and von Willebrand Disease. Pipeline analysis outlines the major FDA-approved haemophilia products, which include those submitted for regulatory review and those in Phase I, II, and III of clinical development. The study also provides an overview of the major clinical trials of recently approved or late-stage pipeline candidates. Novel technologies to extend product half-life and potential future therapies for haemophilia patients have also been discussed.

Table of Contents

Executive SummaryExecutive Summary—Key FindingsExecutive Summary—Key Findings (continued)Haemophilia Drugs Market—Game-changing StrategiesKey Merger, Acquisition, and Partnership AssessmentKey Merger, Acquisition, and Partnership Assessment (continued)Methodology and ScopeIntroductionIntroduction Introduction (continued) Classification of HaemophiliaTreatment Guidelines for Haemophilia Therapy—Prophylactic or On-demandMarket Overview—SegmentationMarket Overview—Segmentation (continued)Haemophilia Therapeutics Market—Epidemiology and Patient ForecastsHaemophilia—Prevalence and IncidenceHaemophilia—Global Prevalence and Treatment RatesHaemophilia Therapeutics Market—Trends and Revenue ForecastsForecast Assumptions and DefinitionsHaemophilia Therapeutics Market—Revenue ForecastRevenue Forecast DiscussionRevenue Forecast Discussion (continued)Increasing Use of Recombinant and Prophylactic TreatmentVariation in Adoption of Prophylactic Therapy by RegionAnnual Switching Rates in HaemophiliaGlobal Haemophilia A and vWD Therapeutics Market Revenue ForecastRevenue Forecast DiscussionRevenue Forecast Discussion (continued)Haemophilia B Therapeutics Market—Revenue ForecastRevenue Forecast DiscussionRevenue Forecast Discussion (continued)Inhibitors (Bypassing Agents) Market—Revenue ForecastRevenue Forecast DiscussionRevenue Forecast Discussion (continued)Haemophilia Therapeutics Market—Marketed Product AnalysisProduct Analysis—F VIII (Haemophilia A) and FVIII/vWF (vWD) Product Analysis—F VIII (Haemophilia A) and FVIII/vWF (vWD) (continued) Product Analysis—F VIII (Haemophilia A) and FVIII/vWF (vWD) (continued) Product Analysis—F VIII (Haemophilia A) and FVIII/vWF (vWD) (continued)Product Analysis—Factor IX (Haemophilia B)Product Analysis—Factor IX (Haemophilia B) (continued) Product Analysis—Factor VIIa (Inhibitors) Haemophilia Therapeutics Market—Pipeline AnalysisHaemophilia Drugs—Competitive Landscape of Products in DevelopmentHaematological Drugs—Pipeline AnalysisPipeline Analysis—F VIII (Haemophilia A) and FVIII/VWF (VWD)Pipeline Analysis—F IX (Haemophilia B)Pipeline Analysis—F VIIa (Inhibitors)Haemophilia Therapeutics Market—Major Clinical MilestonesHaemophilia Therapeutics Market—Major Ongoing/Recently Completed Clinical TrialsHaemophilia Therapeutics Market—Major Ongoing/Recently Completed Clinical Trials (continued)Haemophilia Therapeutics Market—Major Ongoing/Recently Completed Clinical Trials (continued)Haemophilia Therapeutics Market—Product Dashboard of Recently Approved and Late-stage Pipeline Drug CandidatesEloctate—Biogen Idec/SOBINovoEight (Turoctocog alfa)—Novo NordiskBAX 111—BaxterBAX 855—BaxterBAY81-8973—Bayer Nuwiq/Human-cl rhFVIII (simotocog alfa)—OctapharmaBAY94-9027—BayerN8-GP (turoctocog alfa pegol)—Novo Nordisk rVIII-Single Chain—CSL BehringAlprolix—Biogen Idec/SOBIRixubis—BaxterrIX-FP—CSL BehringIB1001—Cangene (Emergent Biosolutions)N9-GP (nonacog beta pegol)—Novo NordiskObizur—Baxter BAX 817—BaxterLR769—rEVO Biologics/LFBHaemophilia Therapeutics Market—Future Therapies and Novel Technologies to Extend Half-life Novel Technologies that Extend Half-life of Factor ConcentratesNovel Technologies that Extend Half-life of Factor Concentrates (continued)Novel Technologies that Extend Half-life of Factor Concentrates (continued)Novel Technologies that Extend Half-life of Factor Concentrates (continued)Novel Pipeline Therapies—Gene TherapyNovel Pipeline Therapies—RNA InterferenceNovel Pipeline Therapies—Tissue Factor Pathway InhibitorHaemophilia Therapeutics Market—Timeline of Key EventsHaemophilia A Therapeutics (FVIII) Market—Timeline of Key EventsHaemophilia B Therapeutics (FIX) Market—Timeline of Key EventsInhibitors (Bypassing Agents) (FVIIa) Market—Timeline of Key EventsHaemophilia Therapeutics Market—Key Companies to Watch Leading Big Pharma Companies—SWOT Analysis BayerLeading Big Pharma Companies—SWOT Analysis BaxterLeading Big Pharma Companies—SWOT Analysis Novo NordiskLeading Big Pharma Companies—SWOT Analysis PfizerKey Companies to Watch—SWOT Analysis Biogen IdecKey Companies to Watch—SWOT Analysis CSL BehringComparative Product Analysis of Key Market ParticipantsConclusionsConclusions and RecommendationsLegal DisclaimerAppendixList of AbbreviationsThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue PropositionGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Related Research

Release Date : 19-Sep-17

Region : South Asia, Middle East & North Africa

Release Date : 11-Sep-17

Region : South Asia, Middle East & North Africa

Release Date : 11-Aug-17

Region : South Asia, Middle East & North Africa

Release Date : 07-Aug-17

Region : South Asia, Middle East & North Africa

Release Date : 19-Jun-17

Region : South Asia, Middle East & North Africa

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.